Tiotropium bromide

Drugs

Volumn 62, Issue 8, 2002, Pages 1195-1203

  Hvizdos, Karen M ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

IPRATROPIUM BROMIDE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; SALMETEROL; TIOTROPIUM BROMIDE;

ANTICHOLINERGIC EFFECT; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DYSPNEA; FORCED EXPIRATORY VOLUME; HUMAN; NONHUMAN; QUALITY OF LIFE; REVIEW; TACHYPHYLAXIS; VITAL CAPACITY; XEROSTOMIA;

EID: 0036271323     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262080-00008     Document Type: Review

References (32)

1. BTS guidelines for the management of chronic obstructive pulmonary disease
2. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease
3. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global initiative for chronic Obstructive Lung Disease (GOLD) workshop summary
4. Muscarinic receptor subtypes and smooth muscle function
5. Characterization of [3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: Radioligand binding and autoradiographic mapping
6. Ba 679 BR, a novel long-acting anticholinergic bronchodilator
7. Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways
8. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: A pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD)
9. The timing of dose and pattern of bronchodilatation of tiotropium (TIO) in stable COPD
10. Effect of tiotropium on distribution pattern of aerosol particles deposited in the lung
11. Effect of tiotropium on lung ventilatory distribution in COPD patients
12. Effects of anticholinergic therapy (tiotropium) on REM-related desaturation (SaO2) and sleep quality in patients with COPD
13. Tiotropium (Spiriva): Mechanistical considerations and clinical profile in obstructive lung disease
14. The pharmacokinetic (PK) profile of tiotropium during long-term treatment in stable COPD
15. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium
16. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease
17. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease
18. A 6-month placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol
19. Tiotropium (Spiriva): One year bronchodilator efficacy established with once daily dosing in COPD patients
20. Tiotropium (Spiriva) improves health status in patients with COPD
21. Tiotropium (Spiriva), a new long-acting anticholinergic bronchodilator, improves dyspnea in patients with COPD
22. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD
23. Efficacy of once daily tiotropium (TIO) in stable COPD
24. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease
25. Once-daily tiotropium (TIO) is more efficacious than q.i.d. ipratropium (IB) as maintenance treatment of COPD
26. Maintenance of bronchodilation following tiotropium in patients with mild, moderate and severe COPD in one year clinical trials
27. Improvements in COPD following treatment with tiotropium in elderly patients
28. Influence of gender on outcomes in large COPD clinical trials
29. Superior bronchodilator effects of tiotropium (TIO) vs. ipratropium (IB) in COPD over a one year clinical trial
30. Compliance with tiotropium, a once daily dry powder inhaled bronchodilator, in one year COPD trials
31. Effective use of HandiHaler dry powder inhalation system over a range of COPD disease severity
32. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire